EyePoint Pharmaceuticals/$EYPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Ticker
$EYPT
Sector
Primary listing
Employees
165
Headquarters
Website
EYPT Metrics
BasicAdvanced
$826M
-
-$2.71
1.75
-
Price and volume
Market cap
$826M
Beta
1.75
52-week high
$14.91
52-week low
$3.91
Average daily volume
1.3M
Financial strength
Current ratio
7.996
Quick ratio
7.727
Long term debt to equity
8.868
Total debt to equity
9.685
Interest coverage (TTM)
-13,503.64%
Profitability
EBITDA (TTM)
-187.182
Gross margin (TTM)
-257.63%
Net profit margin (TTM)
-337.93%
Operating margin (TTM)
-364.27%
Effective tax rate (TTM)
-0.10%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-37.79%
Return on equity (TTM)
-73.95%
Valuation
Price to revenue (TTM)
14.933
Price to book
3.35
Price to tangible book (TTM)
3.35
Price to free cash flow (TTM)
-3.994
Free cash flow yield (TTM)
-25.04%
Free cash flow per share (TTM)
-2.999
Growth
Revenue change (TTM)
2.99%
Earnings per share change (TTM)
45.72%
3-year revenue growth (CAGR)
7.77%
3-year earnings per share growth (CAGR)
6.39%
What the Analysts think about EYPT
Analyst ratings (Buy, Hold, Sell) for EyePoint Pharmaceuticals stock.
Bulls say / Bears say
The company completed enrollment of over 800 patients in its pivotal Phase 3 LUGANO and LUCIA trials for DURAVYU™ in wet AMD in a record seven months, showing strong physician and patient interest and speeding up the path to potential approval (GlobeNewswire).
EyePoint’s commercial manufacturing facility in Northbridge, MA is now operational and has started DURAVYU™ registration batches, preparing the company to support a potential NDA submission and meet expected market demand (GlobeNewswire).
With $256 million in cash, cash equivalents, and marketable securities as of June 30, 2025, EyePoint has secured funding into 2027, covering operations beyond topline Phase 3 data for DURAVYU™ in 2026 and lowering near-term financing risk (GlobeNewswire).
Total net revenue dropped 44% year-over-year to $5.3 million in Q2 2025, down from $9.5 million the previous year, mainly due to lower deferred revenue recognition from the 2023 YUTIQ® licensing agreement, highlighting difficult revenue trends (GlobeNewswire).
Operating expenses increased 54% year-over-year to $67.6 million in Q2 2025, primarily driven by higher clinical trial costs for the ongoing DURAVYU™ Phase 3 LUGANO and LUCIA studies, increasing net loss to $59.4 million (–$0.85 per share) and putting pressure on short-term profitability (GlobeNewswire).
Cash reserves decreased from $371 million as of December 31, 2024 to $256 million as of June 30, 2025, representing a $115 million outflow over six months and reducing the financial cushion ahead of key data releases (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
EYPT Financial Performance
Revenues and expenses
EYPT Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for EyePoint Pharmaceuticals stock?
EyePoint Pharmaceuticals (EYPT) has a market cap of $826M as of October 25, 2025.
What is the P/E ratio for EyePoint Pharmaceuticals stock?
The price to earnings (P/E) ratio for EyePoint Pharmaceuticals (EYPT) stock is 0 as of October 25, 2025.
Does EyePoint Pharmaceuticals stock pay dividends?
No, EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders as of October 25, 2025.
When is the next EyePoint Pharmaceuticals dividend payment date?
EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders.
What is the beta indicator for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals (EYPT) has a beta rating of 1.75. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.